 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan; Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan; Pharmacology and Molecular Biology Research Laboratories, Sankyo, Tokyo, Japan; and Service de Nephrologie, Universite Catholique de Louvain, Brussels, Belgium.
Correspondence to Dr. Toshio Miyata, Molecular and Cellular Nephrology, Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. Phone: 81-463-93-1936; Fax: 81-463-93-1938;
ABSTRACT. Prevention or retardation of diabetic nephropathy (DN) includes anti-hypertensive treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on the premises that these drugs have an added protective effect beyond their influence on BP. The present study used a strain of spontaneously hypertensive/NIH-corpulent rats [SHR/NDmc-cp (fat/fat)] as a model of type II DN to unravel the renoprotective effects of anti-hypertensive drugs. Olmesartan (1 or 5 mg/kg per d), an ARB, and hydralazine (5mg/kg per d), an anti-hypertensive drug without effect on the renin-angiotensin system (RAS), were given for 20 wk. BP, renal function, glucose and insulin levels, and proteinuria were monitored. Glomerular lesions and kidney pentosidine content were assessed at the end of the study. Olmesartan (1 and 5 mg) significantly reduced BP and kidney pentosidine content and improved histologic renal damage and proteinuria. The changes were dose-dependent. The effect of hydralazine (5 mg) was similar to that of olmesartan (1 mg) but reached statistical significance only for kidney pentosidine content. The similarity of both drugs’ effects on kidney damage and proteinuria suggest that renoprotection does not hinge on manipulation of RAS in these rats. By contrast, the inhibition of renal pentosidine formation assessed both by immunohistochemistry and HPLC suggests a critical role of advanced glycation end product (AGE) formation together with hypertension in the genesis of diabetic nephropathy. This view is supported by the correlation found between renal pentosidine content and proteinuria. The unsuspected AGE-lowering effect of hydralazine was further confirmed in vitro and elucidated; it is due to both reactive carbonyl compounds trapping and modifications of the oxidative metabolism. It is concluded that AGE inhibition should be included in the therapeutic strategy of DN. E-mail: t-miyata@is.icc.u-tokai.ac.jp
This article has been cited by other articles:
 |
|
 |
|
  Y. Izuhara, T. Sada, H. Yanagisawa, H. Koike, S. Ohtomo, T. Dan, S. Ito, M. Nangaku, C. van Ypersele de Strihou, and T. Miyata A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1767 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ohtomo, M. Nangaku, Y. Izuhara, S. Takizawa, C. v. Y. d. Strihou, and T. Miyata Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1166 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Goh and M. E. Cooper The Role of Advanced Glycation End Products in Progression and Complications of Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Izuhara, M. Nangaku, S. Takizawa, S. Takahashi, J. Shao, H. Oishi, H. Kobayashi, C. van Ypersele de Strihou, and T. Miyata A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models Nephrol. Dial. Transplant., February 1, 2008; 23(2): 497 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kojima, T. Tanaka, R. Inagi, H. Kato, T. Yamashita, A. Sakiyama, O. Ohneda, N. Takeda, M. Sata, T. Miyata, et al. Protective Role of Hypoxia-Inducible Factor-2{alpha} against Ischemic Damage and Oxidative Stress in the Kidney J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1218 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. L. Hartog, A. P. J. de Vries, S. J. L. Bakker, R. Graaff, W. J. van Son, J. J. H. van der Heide, R. O. B. Gans, B. H. R. Wolffenbuttel, P. E. de Jong, and A. J. Smit Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2263 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miyata and C. van Ypersele de Strihou Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering Nephrol. Dial. Transplant., April 1, 2006; 21(4): 846 - 849. [Full Text] [PDF]
|
|
|
|
|
|
M. Nangaku, Y. Izuhara, N. Usuda, R. Inagi, T. Shibata, S. Sugiyama, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2661 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Izuhara, M. Nangaku, R. Inagi, N. Tominaga, T. Aizawa, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3631 - 3641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Forbes, S. R. Thorpe, V. Thallas-Bonke, J. Pete, M. C. Thomas, E. R. Deemer, S. Bassal, A. El-Osta, D. M. Long, S. Panagiotopoulos, et al. Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2363 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Harris Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy: It's All the RAGE J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2251 - 2253. [Full Text] [PDF]
|
|
|
|
|
|
Q. Fan, J. Liao, M. Kobayashi, M. Yamashita, L. Gu, T. Gohda, Y. Suzuki, L. N. Wang, S. Horikoshi, and Y. Tomino Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3012 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Burcham, F. R. Fontaine, L. M. Kaminskas, D. R. Petersen, and S. M. Pyke Protein Adduct-Trapping by Hydrazinophthalazine Drugs: Mechanisms of Cytoprotection Against Acrolein-Mediated Toxicity Mol. Pharmacol., March 1, 2004; 65(3): 655 - 664. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
